Back pain after photodynamic therapy with verteporfin

Alfredo Pece, Maria Vadalà, Renato Manzi, Giliola Calori

Research output: Contribution to journalArticle

Abstract

PURPOSE: To report the incidence of back pain after photodynamic therapy, which suggests methods for prevention that are related to its pathogenesis. DESIGN: Retrospective case series. METHODS: We retrospectively observed 548 patients who had undergone photodynamic therapy with verteporfin. RESULTS: Of 548 patients at the first treatment, 14 patients (2.6%) experienced pain during the infusion. Eleven patients were being treated for age-related macular degeneration; their mean age was 81 years, which significantly differed from the mean age of the overall age-related macular degeneration group (P = .003). The pain was mild in eight patients, moderate in four patients, and severe in two patients, with dyspnea and precordial pain. Five of the 14 patients had further courses of photodynamic therapy. After being treated prophylactically 60 minutes before photodynamic therapy, only one patient reported further mild pain. CONCLUSIONS: The biologic mechanisms of back pain may involve a high level of circulating thromboxanes that are induced by the liposomal composition of verteporfin. Prevention may include hydration, nonsteroidal anti-inflammatory drugs, and halving the infusion rate.

Original languageEnglish
Pages (from-to)593-594
Number of pages2
JournalAmerican Journal of Ophthalmology
Volume141
Issue number3
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Photochemotherapy
Back Pain
Pain
Macular Degeneration
verteporfin
Thromboxanes
Dyspnea
Anti-Inflammatory Agents
Incidence

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Back pain after photodynamic therapy with verteporfin. / Pece, Alfredo; Vadalà, Maria; Manzi, Renato; Calori, Giliola.

In: American Journal of Ophthalmology, Vol. 141, No. 3, 03.2006, p. 593-594.

Research output: Contribution to journalArticle

Pece, Alfredo ; Vadalà, Maria ; Manzi, Renato ; Calori, Giliola. / Back pain after photodynamic therapy with verteporfin. In: American Journal of Ophthalmology. 2006 ; Vol. 141, No. 3. pp. 593-594.
@article{d2871548817b4c158b16b008037a8b8d,
title = "Back pain after photodynamic therapy with verteporfin",
abstract = "PURPOSE: To report the incidence of back pain after photodynamic therapy, which suggests methods for prevention that are related to its pathogenesis. DESIGN: Retrospective case series. METHODS: We retrospectively observed 548 patients who had undergone photodynamic therapy with verteporfin. RESULTS: Of 548 patients at the first treatment, 14 patients (2.6{\%}) experienced pain during the infusion. Eleven patients were being treated for age-related macular degeneration; their mean age was 81 years, which significantly differed from the mean age of the overall age-related macular degeneration group (P = .003). The pain was mild in eight patients, moderate in four patients, and severe in two patients, with dyspnea and precordial pain. Five of the 14 patients had further courses of photodynamic therapy. After being treated prophylactically 60 minutes before photodynamic therapy, only one patient reported further mild pain. CONCLUSIONS: The biologic mechanisms of back pain may involve a high level of circulating thromboxanes that are induced by the liposomal composition of verteporfin. Prevention may include hydration, nonsteroidal anti-inflammatory drugs, and halving the infusion rate.",
author = "Alfredo Pece and Maria Vadal{\`a} and Renato Manzi and Giliola Calori",
year = "2006",
month = "3",
doi = "10.1016/j.ajo.2005.10.042",
language = "English",
volume = "141",
pages = "593--594",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Back pain after photodynamic therapy with verteporfin

AU - Pece, Alfredo

AU - Vadalà, Maria

AU - Manzi, Renato

AU - Calori, Giliola

PY - 2006/3

Y1 - 2006/3

N2 - PURPOSE: To report the incidence of back pain after photodynamic therapy, which suggests methods for prevention that are related to its pathogenesis. DESIGN: Retrospective case series. METHODS: We retrospectively observed 548 patients who had undergone photodynamic therapy with verteporfin. RESULTS: Of 548 patients at the first treatment, 14 patients (2.6%) experienced pain during the infusion. Eleven patients were being treated for age-related macular degeneration; their mean age was 81 years, which significantly differed from the mean age of the overall age-related macular degeneration group (P = .003). The pain was mild in eight patients, moderate in four patients, and severe in two patients, with dyspnea and precordial pain. Five of the 14 patients had further courses of photodynamic therapy. After being treated prophylactically 60 minutes before photodynamic therapy, only one patient reported further mild pain. CONCLUSIONS: The biologic mechanisms of back pain may involve a high level of circulating thromboxanes that are induced by the liposomal composition of verteporfin. Prevention may include hydration, nonsteroidal anti-inflammatory drugs, and halving the infusion rate.

AB - PURPOSE: To report the incidence of back pain after photodynamic therapy, which suggests methods for prevention that are related to its pathogenesis. DESIGN: Retrospective case series. METHODS: We retrospectively observed 548 patients who had undergone photodynamic therapy with verteporfin. RESULTS: Of 548 patients at the first treatment, 14 patients (2.6%) experienced pain during the infusion. Eleven patients were being treated for age-related macular degeneration; their mean age was 81 years, which significantly differed from the mean age of the overall age-related macular degeneration group (P = .003). The pain was mild in eight patients, moderate in four patients, and severe in two patients, with dyspnea and precordial pain. Five of the 14 patients had further courses of photodynamic therapy. After being treated prophylactically 60 minutes before photodynamic therapy, only one patient reported further mild pain. CONCLUSIONS: The biologic mechanisms of back pain may involve a high level of circulating thromboxanes that are induced by the liposomal composition of verteporfin. Prevention may include hydration, nonsteroidal anti-inflammatory drugs, and halving the infusion rate.

UR - http://www.scopus.com/inward/record.url?scp=33144476278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33144476278&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2005.10.042

DO - 10.1016/j.ajo.2005.10.042

M3 - Article

C2 - 16490525

AN - SCOPUS:33144476278

VL - 141

SP - 593

EP - 594

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 3

ER -